收藏切换
Meta-analysis of the efficacy and safety of tenofovir and entecavir in the treatment of chronic hepatitis B cirrhosis
收藏切换
Zhenling ZHU, Ling GU*
World Clinical Drug | 2025, 46(5) : 501 - 509
Less
收藏切换
World Clinical Drug | 2025, 46(5): 501-509
• Article •
Meta-analysis of the efficacy and safety of tenofovir and entecavir in the treatment of chronic hepatitis B cirrhosis
Full
Zhenling ZHU, Ling GU*
Affiliations
  • Department of Pharmacy, Taixing People's Hospital, Taixing 225400, Jiangsu Province, China
Published: 2025-05-10 doi: 10.13683/j.wph.2025.05.013
Outline
收藏切换
Objective

Based on the published literature and the data from completed clinical trials, the meta-analysis method was used to systematically evaluate the efficacy and safety of tenofovir and entecavir in the treatment of patients with chronic hepatitis B (CHB) cirrhosis.

Methods

PubMed, Web of Science, Embase, Clinicaltrials.gov, Cochrane library, China Biomedical Literature Service System database, China National Knowledge Infrastructure and Wanfang database were comprehensively searched. The search period was from the establishment date of the database to May 2024. The research data of tenofovir and entecavir in the treatment of patients with CHB cirrhosis were collected. The Cochrane systematic review method was used to screen the literature, evaluate the quality of the included literature, and extract the included characteristic information for meta-analysis. The outcome indicators included the negative conversion rate of hepatitis B virus (HBV)-DNA, the normalization rate of glutamic-pyruvic transaminase (GPT), the cumulative incidence of hepatocellular carcinoma (HCC), the cumulative mortality rate and the changes in estimated glomerular filtration rate (eGFR).

Results

A total of 18 articles were included, involving 13 251 patients. The results showed that at 24 and 48 weeks of treatment, compared with entecavir, the negative conversion rate of HBV-DNA in the tenofovir group[odds ratio (OR)=0.84, 95% confidence interval (CI): 0.65—1.08, P=0.17; OR=0.98, 95%CI: 0.28—3.51, P=0.98] and the normalization rate of GPT (OR=1.12, 95%CI: 0.55—2.28, P=0.76; OR=1.35, 95%CI: 0.77—2.36, P=0.29) basically equivalent; Tenofovir can significantly reduce the incidence of cumulative HCC in patients (OR=0.57, 95%CI: 0.42—0.77, P=0.0003), However, there were no significant differences in cumulative mortality (OR=0.89, 95%CI: 0.44—1.83, P=0.76)and the change of eGFR changes (standardized mean difference: -3.02, 95%CI: -18.46—12.42, P=0.70)between the two groups.

Conclusion

Tenofovir and entecavir are basically equivalent in the treatment of CHB cirrhosis patients in terms of HBV-DNA negative conversion rate, eGPT normalization rate, cumulative mortality rate and renal function damage, while the former can significantly reduce the incidence of HCC in patients.

tenofovir  /  entecavir  /  chronic hepatitis B  /  liver cirrhosis  /  meta-analysis
朱振玲, 顾玲. 替诺福韦与恩替卡韦在治疗慢性乙型肝炎肝硬化有效性和安全性的meta分析. 世界临床药物, 2025 , 46 (5) : 501 -509 . DOI: 10.13683/j.wph.2025.05.013
Zhenling ZHU, Ling GU. Meta-analysis of the efficacy and safety of tenofovir and entecavir in the treatment of chronic hepatitis B cirrhosis[J]. World Clinical Drug, 2025 , 46 (5) : 501 -509 . DOI: 10.13683/j.wph.2025.05.013
Year 2025 volume 46 Issue 5
54
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.05.013
  • Receive Date:2024-09-29
  • Online Date:2026-11-09
  • Published:2025-05-10
Article Data
Affiliations
History
  • Received:2024-09-29
Funding
Affiliations
    Department of Pharmacy, Taixing People's Hospital, Taixing 225400, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.05.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT